Prescription practices showed that 10.8% (n=27) of participants always prescribed SGLT-2 inhibitors for heart failure, and 8.8% (n=22) always prescribed GLP-1 agonists for cardiometabolic diseases. The gene discussed is GLP1R; the disease is heart failure.